Cost-effectiveness analysis of ibrutinib in patients with Waldenström macroglobulinemia in Italy

Luca Laurenti, Andrea Aiello, Anna D'Ausilio, Roberta Lo Muto, Francesca Randon

Risultato della ricerca: Contributo in rivistaArticolo in rivista

Abstract

Ibrutinib has recently been approved in Europe for Waldenström Macroglobulinemia (WM) in symptomatic patients who have received at least one prior therapy, or in first-line treatment for patients unsuitable for chemo-immunotherapy. The aim of the study is to estimate the incremental cost-effectiveness ratio (ICER) of ibrutinib in relapse/refractory WM, compared with the Italian current therapeutic pathways (CTP).
Lingua originaleEnglish
pagine (da-a)N/A-N/A
RivistaJOURNAL OF MARKET ACCESS & HEALTH POLICY
Volume5
DOI
Stato di pubblicazionePubblicato - 2017

Keywords

  • Italy
  • Waldenström Macroglobulinemia
  • cost-effectiveness analysis
  • ibrutinib

Fingerprint

Entra nei temi di ricerca di 'Cost-effectiveness analysis of ibrutinib in patients with Waldenström macroglobulinemia in Italy'. Insieme formano una fingerprint unica.

Cita questo